Sun Pharma enters licensing agreement with CMS for arthritis drug Tildrakizumab Medical Dialogues Bureau28 Jun 2019 7:00 AM GMTThe initial tenure of the agreement between Sun Pharma and CMS shall be 15 years from the first commercial sale of Tildrakizumab in Greater China and...